Holen Sie sich die Stockscreener-App
12.10
12.00%
-1.65
Handel nachbörslich:
12.28
0.18
+1.49%
Schlusskurs vom Vortag:
$13.75
Offen:
$13.76
24-Stunden-Volumen:
384.99K
Relative Volume:
1.68
Marktkapitalisierung:
$1.54B
Einnahmen:
-
Nettoeinkommen (Verlust:
-
KGV:
-
EPS:
-
Netto-Cashflow:
-
1W Leistung:
+5.13%
1M Leistung:
+7.94%
6M Leistung:
+0.00%
1J Leistung:
+0.00%
1-Tages-Spanne:
$11.96
$13.97
1-Wochen-Bereich:
$11.15
$14.21
52-Wochen-Spanne:
$11.00
$14.21
Generate Biomedicines Inc Stock (GENB) Company Profile
Firmenname
Generate Biomedicines Inc
Sektor
Branche
Telefon
-
Adresse
-
Compare GENB vs VRTX, REGN, ARGX, ALNY, INSM
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
GENB
Generate Biomedicines Inc
|
12.10 | 1.75B | 0 | 0 | 0 | 0.00 |
VRTX
Vertex Pharmaceuticals Inc
|
434.30 | 111.45B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
763.04 | 80.54B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
748.25 | 46.32B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
330.34 | 42.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
INSM
Insmed Inc
|
163.81 | 35.01B | 606.42M | -1.28B | -997.58M | -6.403 |
Generate Biomedicines Inc Stock (GENB) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-03-24 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2026-03-24 | Eingeleitet | Goldman | Buy |
| 2026-03-24 | Eingeleitet | Guggenheim | Buy |
| 2026-03-24 | Eingeleitet | Morgan Stanley | Overweight |
| 2026-03-24 | Eingeleitet | Piper Sandler | Overweight |
Generate Biomedicines Inc Aktie (GENB) Neueste Nachrichten
Top Generate Biomedicines (GENB) Competitors 2026 - marketbeat.com
Cantor Fitzgerald reiterates Generate Biomedicines stock rating By Investing.com - Investing.com Canada
IPO Tracker 2026: Biotech Mega-Rounder Kailera Seeks IPO - BioSpace
Kailera Therapeutics files for US IPO - MarketScreener
Flagship-backed Generate Bio seeks $425 million in US IPO - MSN
Generate Biomedicines (NASDAQ:GENB) Rating Increased to Hold at Zacks Research - marketbeat.com
Generate Biomedicines, Inc.Common Stock (Nasdaq:GENB) Stock Quote - FinancialContent
This KB Home Analyst Begins Coverage On A Bullish Note; Here Are Top 4 Initiations For Tuesday - Sahm
Generate Biomedicines gains buy initiations from Guggenheim, Piper Sandler - Seeking Alpha
The Goldman Sachs Group Initiates Coverage on Generate Biomedicines (NASDAQ:GENB) - MarketBeat
Morgan Stanley Initiates Coverage on Generate Biomedicines (NASDAQ:GENB) - marketbeat.com
Generate Biomedicines (NASDAQ:GENB) Coverage Initiated at Guggenheim - marketbeat.com
Generate Biomedicines (NASDAQ:GENB) Earns Overweight Rating from Analysts at Cantor Fitzgerald - MarketBeat
Goldman Sachs Initiates Coverage on Generate Biomedicines With Buy Rating, $26 Price Target - marketscreener.com
Guggenheim Initiates Coverage on Generate Biomedicines With Buy Rating, $30 Price Target - marketscreener.com
Piper Sandler initiates Generate Biomedicines stock at overweight By Investing.com - Investing.com Canada
Morgan Stanley Initiates Generate Biomedicines at Overweight With $20 Price Target - marketscreener.com
Morgan Stanley initiates Generate Biomedicines stock at overweight By Investing.com - Investing.com Canada
Piper Sandler initiates Generate Biomedicines stock at overweight - Investing.com
Morgan Stanley initiates Generate Biomedicines stock at overweight - Investing.com
Goldman Sachs initiates Generate Biomedicines stock with buy rating on AI platform potential - Investing.com
Guggenheim initiates Generate Biomedicines stock with buy rating By Investing.com - Investing.com Australia
Guggenheim initiates Generate Biomedicines stock with buy rating - investing.com
ETFs Investing in Generate Biomedicines, Inc. Stocks - TradingView
Generate Biomedicines IPO Turns Heads - Yahoo! Finance Canada
Generate Biomedicines (GENB) Stock Trends and Sentiment 2026 - MarketBeat
Free cash flow per share of Generate Biomedicines, Inc. – NASDAQ:GENB - TradingView
GENB | Generate Biomedicines, Inc. Common Stock Data, Price & News - Quiver Quantitative
Total debt per share of Generate Biomedicines, Inc. – NASDAQ:GENB - TradingView
Book value per share of Generate Biomedicines, Inc. – NASDAQ:GENB - TradingView
Revenue per share of Generate Biomedicines, Inc. – NASDAQ:GENB - TradingView
Generate Biomedicines (GENB) 10K Form and SEC Filings 2026 - MarketBeat
Total liabilities & shareholders' equities of Generate Biomedicines, Inc. – NASDAQ:GENB - TradingView
After tax other income/expense of Generate Biomedicines, Inc. – NASDAQ:GENB - TradingView
Gross profit of Generate Biomedicines, Inc. – NASDAQ:GENB - TradingView
EBIT of Generate Biomedicines, Inc. – NASDAQ:GENB - TradingView
Total revenue of Generate Biomedicines, Inc. – NASDAQ:GENB - TradingView
Average basic shares outstanding of Generate Biomedicines, Inc. – NASDAQ:GENB - TradingView
Cash per share of Generate Biomedicines, Inc. – NASDAQ:GENB - TradingView
Pretax income of Generate Biomedicines, Inc. – NASDAQ:GENB - TradingView
Generate Biomedicines, Inc. Income Statement – NASDAQ:GENB - TradingView
Generate Biomedicines, Inc. Dividends – NASDAQ:GENB - TradingView
Net debt of Generate Biomedicines, Inc. – NASDAQ:GENB - TradingView
Tangible book value per share of Generate Biomedicines, Inc. – NASDAQ:GENB - TradingView
Cash from investing activities of Generate Biomedicines, Inc. – NASDAQ:GENB - TradingView
Free cash flow of Generate Biomedicines, Inc. – NASDAQ:GENB - TradingView
Generate Biomedicines, Inc. Cash Flow – NASDAQ:GENB - TradingView
Long term debt to total assets ratio of Generate Biomedicines, Inc. – NASDAQ:GENB - TradingView
Total liabilities of Generate Biomedicines, Inc. – NASDAQ:GENB - TradingView
Enterprise value to EBITDA ratio of Generate Biomedicines, Inc. – NASDAQ:GENB - TradingView
Price to sales ratio of Generate Biomedicines, Inc. – NASDAQ:GENB - TradingView
Finanzdaten der Generate Biomedicines Inc-Aktie (GENB)
Es liegen keine Finanzdaten für Generate Biomedicines Inc (GENB) vor. Überprüfen Sie andere Aktien für weitere Informationen.
Umsatz
Nettogewinn
Free Cashflow
ENV
Generate Biomedicines Inc-Aktie (GENB) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Grous Beth | Chief People Officer |
Mar 02 '26 |
Buy |
16.00 |
300 |
4,800 |
300 |
| Silvers Jason | President & CFO |
Mar 02 '26 |
Buy |
16.00 |
2,000 |
32,000 |
1,000 |
| AFEYAN NOUBAR | Director |
Mar 02 '26 |
Buy |
16.00 |
4,687,500 |
75,000,000 |
15,264,724 |
| Mendillo Jane L | Director |
Mar 02 '26 |
Buy |
16.00 |
1,500 |
24,000 |
1,500 |
| AFEYAN NOUBAR | Director |
Mar 02 '26 |
Buy |
16.00 |
4,687,500 |
75,000,000 |
15,264,724 |
0.87%
0.11%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):